Do analysts prefer IMCC or ITRM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IM Cannabis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Iterum Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Is IMCC or ITRM more profitable?

Iterum Therapeutics has a net margin of 0.00% compared to IM Cannabis' net margin of -39.62%. Company Net Margins Return on Equity Return on Assets IM Cannabis -39.62% N/A -58.32% Iterum Therapeutics N/A N/A -65.54%

Do analysts rate IMCC or NKGN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IM Cannabis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 NKGen Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is IMCC or NKGN more profitable?

NKGen Biotech has a net margin of 0.00% compared to IM Cannabis' net margin of -39.62%. Company Net Margins Return on Equity Return on Assets IM Cannabis -39.62% N/A -58.32% NKGen Biotech N/A N/A -479.36%

Do analysts rate SXTC or IMCC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score China SXT Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 IM Cannabis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, SXTC or IMCC?

China SXT Pharmaceuticals has higher earnings, but lower revenue than IM Cannabis. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio China SXT Pharmaceuticals $1.14M 0.04 -$6.20M N/A N/A IM Cannabis $39.17M 0.01 -$8.10M -$60.66 N/A

Is SXTC or IMCC more profitable?

China SXT Pharmaceuticals has a net margin of 0.00% compared to IM Cannabis' net margin of -39.62%. Company Net Margins Return on Equity Return on Assets China SXT Pharmaceuticals N/A N/A N/A IM Cannabis -39.62% N/A -58.32%

Does the media refer more to SXTC or IMCC?

In the previous week, China SXT Pharmaceuticals had 9 more articles in the media than IM Cannabis. MarketBeat recorded 12 mentions for China SXT Pharmaceuticals and 3 mentions for IM Cannabis. China SXT Pharmaceuticals' average media sentiment score of 0.43 beat IM Cannabis' score of 0.16 indicating that China SXT Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment China SXT Pharmaceuticals 1 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral IM Cannabis 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate IMCC or JAGX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IM Cannabis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Jaguar Animal Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, IMCC or JAGX?

IM Cannabis has higher revenue and earnings than Jaguar Animal Health. IM Cannabis is trading at a lower price-to-earnings ratio than Jaguar Animal Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IM Cannabis $39.17M 0.01 -$8.10M -$60.66 N/A Jaguar Animal Health $11.51M 0.14 -$53.43M -$3.73 thousand N/A

Is IMCC or JAGX more profitable?

IM Cannabis has a net margin of -39.62% compared to Jaguar Animal Health's net margin of -187.88%. Company Net Margins Return on Equity Return on Assets IM Cannabis -39.62% N/A -58.32% Jaguar Animal Health -187.88% N/A -131.45%

Does the media favor IMCC or JAGX?

In the previous week, Jaguar Animal Health had 5 more articles in the media than IM Cannabis. MarketBeat recorded 8 mentions for Jaguar Animal Health and 3 mentions for IM Cannabis. Jaguar Animal Health's average media sentiment score of 0.30 beat IM Cannabis' score of 0.16 indicating that Jaguar Animal Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IM Cannabis 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Jaguar Animal Health 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts recommend IMCC or ATXI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IM Cannabis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Avenue Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

IM Cannabis (IMCC) Competitors

$1.33 -0.13 (-8.90%)

As of 02:31 PM Eastern

Compare

IMCC vs. ITRM, NKGN, SXTC, JAGX, and ATXI

Should you buy IM Cannabis stock or one of its competitors? IM Cannabis's main competitors and comparable companies include Iterum Therapeutics (ITRM), NKGen Biotech (NKGN), China SXT Pharmaceuticals (SXTC), Jaguar Animal Health (JAGX), and Avenue Therapeutics (ATXI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does IM Cannabis compare to Iterum Therapeutics?

IM Cannabis (NASDAQ:IMCC) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, media sentiment, profitability, valuation and dividends.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IM Cannabis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Iterum Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Iterum Therapeutics has a net margin of 0.00% compared to IM Cannabis' net margin of -39.62%.

Company	Net Margins	Return on Equity	Return on Assets
IM Cannabis	-39.62%	N/A	-58.32%
Iterum Therapeutics	N/A	N/A	-65.54%

IM Cannabis has a beta of 2.21, suggesting that its share price is 121% more volatile than the broader market. Comparatively, Iterum Therapeutics has a beta of 2.96, suggesting that its share price is 196% more volatile than the broader market.

7.7% of IM Cannabis shares are owned by institutional investors. Comparatively, 9.2% of Iterum Therapeutics shares are owned by institutional investors. 2.0% of Iterum Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

IM Cannabis has higher revenue and earnings than Iterum Therapeutics. Iterum Therapeutics is trading at a lower price-to-earnings ratio than IM Cannabis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IM Cannabis	$39.17M	0.01	-$8.10M	-$60.66	N/A
Iterum Therapeutics	$390K	4.10	-$24.77M	-$0.75	N/A

In the previous week, IM Cannabis had 3 more articles in the media than Iterum Therapeutics. MarketBeat recorded 3 mentions for IM Cannabis and 0 mentions for Iterum Therapeutics. IM Cannabis' average media sentiment score of 0.16 beat Iterum Therapeutics' score of 0.00 indicating that IM Cannabis is being referred to more favorably in the media.

Company	Overall Sentiment
IM Cannabis	Neutral
Iterum Therapeutics	Neutral

Summary

Iterum Therapeutics beats IM Cannabis on 7 of the 13 factors compared between the two stocks.

How does IM Cannabis compare to NKGen Biotech?

IM Cannabis (NASDAQ:IMCC) and NKGen Biotech (NYSE:NKGN) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, dividends, risk and analyst recommendations.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IM Cannabis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NKGen Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, IM Cannabis had 3 more articles in the media than NKGen Biotech. MarketBeat recorded 3 mentions for IM Cannabis and 0 mentions for NKGen Biotech. IM Cannabis' average media sentiment score of 0.16 beat NKGen Biotech's score of 0.00 indicating that IM Cannabis is being referred to more favorably in the media.

Company	Overall Sentiment
IM Cannabis	Neutral
NKGen Biotech	Neutral

IM Cannabis has a beta of 2.21, indicating that its stock price is 121% more volatile than the broader market. Comparatively, NKGen Biotech has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market.

7.7% of IM Cannabis shares are held by institutional investors. Comparatively, 76.2% of NKGen Biotech shares are held by institutional investors. 10.4% of NKGen Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

IM Cannabis has higher revenue and earnings than NKGen Biotech. IM Cannabis is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IM Cannabis	$39.17M	0.01	-$8.10M	-$60.66	N/A
NKGen Biotech	N/A	N/A	-$82.94M	-$1.68	N/A

NKGen Biotech has a net margin of 0.00% compared to IM Cannabis' net margin of -39.62%.

Company	Net Margins	Return on Equity	Return on Assets
IM Cannabis	-39.62%	N/A	-58.32%
NKGen Biotech	N/A	N/A	-479.36%

Summary

IM Cannabis beats NKGen Biotech on 7 of the 12 factors compared between the two stocks.

How does IM Cannabis compare to China SXT Pharmaceuticals?

China SXT Pharmaceuticals (NASDAQ:SXTC) and IM Cannabis (NASDAQ:IMCC) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, media sentiment, valuation and risk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
China SXT Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
IM Cannabis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

China SXT Pharmaceuticals has a net margin of 0.00% compared to IM Cannabis' net margin of -39.62%.

Company	Net Margins	Return on Equity	Return on Assets
China SXT Pharmaceuticals	N/A	N/A	N/A
IM Cannabis	-39.62%	N/A	-58.32%

5.0% of China SXT Pharmaceuticals shares are owned by institutional investors. Comparatively, 7.7% of IM Cannabis shares are owned by institutional investors. 4.0% of China SXT Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, China SXT Pharmaceuticals had 9 more articles in the media than IM Cannabis. MarketBeat recorded 12 mentions for China SXT Pharmaceuticals and 3 mentions for IM Cannabis. China SXT Pharmaceuticals' average media sentiment score of 0.43 beat IM Cannabis' score of 0.16 indicating that China SXT Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
China SXT Pharmaceuticals	1 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
IM Cannabis	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

China SXT Pharmaceuticals has a beta of 1.86, meaning that its share price is 86% more volatile than the broader market. Comparatively, IM Cannabis has a beta of 2.21, meaning that its share price is 121% more volatile than the broader market.

China SXT Pharmaceuticals has higher earnings, but lower revenue than IM Cannabis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China SXT Pharmaceuticals	$1.14M	0.04	-$6.20M	N/A	N/A
IM Cannabis	$39.17M	0.01	-$8.10M	-$60.66	N/A

Summary

China SXT Pharmaceuticals beats IM Cannabis on 7 of the 10 factors compared between the two stocks.

How does IM Cannabis compare to Jaguar Animal Health?

IM Cannabis (NASDAQ:IMCC) and Jaguar Animal Health (NASDAQ:JAGX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends.

In the previous week, Jaguar Animal Health had 5 more articles in the media than IM Cannabis. MarketBeat recorded 8 mentions for Jaguar Animal Health and 3 mentions for IM Cannabis. Jaguar Animal Health's average media sentiment score of 0.30 beat IM Cannabis' score of 0.16 indicating that Jaguar Animal Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IM Cannabis	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Jaguar Animal Health	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IM Cannabis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Jaguar Animal Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

7.7% of IM Cannabis shares are owned by institutional investors. Comparatively, 12.0% of Jaguar Animal Health shares are owned by institutional investors. 0.1% of Jaguar Animal Health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

IM Cannabis has a beta of 2.21, suggesting that its share price is 121% more volatile than the broader market. Comparatively, Jaguar Animal Health has a beta of -0.11, suggesting that its share price is 111% less volatile than the broader market.

IM Cannabis has a net margin of -39.62% compared to Jaguar Animal Health's net margin of -187.88%.

Company	Net Margins	Return on Equity	Return on Assets
IM Cannabis	-39.62%	N/A	-58.32%
Jaguar Animal Health	-187.88%	N/A	-131.45%

IM Cannabis has higher revenue and earnings than Jaguar Animal Health. IM Cannabis is trading at a lower price-to-earnings ratio than Jaguar Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IM Cannabis	$39.17M	0.01	-$8.10M	-$60.66	N/A
Jaguar Animal Health	$11.51M	0.14	-$53.43M	-$3.73 thousand	N/A

Summary

IM Cannabis and Jaguar Animal Health tied by winning 6 of the 12 factors compared between the two stocks.

How does IM Cannabis compare to Avenue Therapeutics?

IM Cannabis (NASDAQ:IMCC) and Avenue Therapeutics (NASDAQ:ATXI) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, media sentiment and institutional ownership.

In the previous week, IM Cannabis had 3 more articles in the media than Avenue Therapeutics. MarketBeat recorded 3 mentions for IM Cannabis and 0 mentions for Avenue Therapeutics. IM Cannabis' average media sentiment score of 0.16 beat Avenue Therapeutics' score of 0.00 indicating that IM Cannabis is being referred to more favorably in the media.

Company	Overall Sentiment
IM Cannabis	Neutral
Avenue Therapeutics	Neutral

IM Cannabis has higher revenue and earnings than Avenue Therapeutics. Avenue Therapeutics is trading at a lower price-to-earnings ratio than IM Cannabis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IM Cannabis	$39.17M	0.01	-$8.10M	-$60.66	N/A
Avenue Therapeutics	N/A	N/A	-$10.38M	-$0.85	N/A

7.7% of IM Cannabis shares are held by institutional investors. Comparatively, 17.3% of Avenue Therapeutics shares are held by institutional investors. 8.6% of Avenue Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IM Cannabis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Avenue Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

IM Cannabis has a beta of 2.21, meaning that its stock price is 121% more volatile than the broader market. Comparatively, Avenue Therapeutics has a beta of -0.23, meaning that its stock price is 123% less volatile than the broader market.

Avenue Therapeutics has a net margin of 0.00% compared to IM Cannabis' net margin of -39.62%. IM Cannabis' return on equity of 0.00% beat Avenue Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IM Cannabis	-39.62%	N/A	-58.32%
Avenue Therapeutics	N/A	-471.57%	-296.50%

Summary

IM Cannabis beats Avenue Therapeutics on 8 of the 13 factors compared between the two stocks.

Get IM Cannabis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMCC vs. The Competition

Export

Metric	IM Cannabis	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$279K	$12.13B	$7.16B	$13.15B
Dividend Yield	N/A	2.63%	2.52%	20.73%
P/E Ratio	-0.02	805.18	275.83	25.74
Price / Sales	0.01	935.57	618.13	101.89
Price / Cash	N/A	15.28	27.30	36.12
Price / Book	-0.09	9.12	10.69	6.02
Net Income	-$8.10M	$2.83B	$3.50B	$380.34M
7 Day Performance	-31.44%	-2.95%	-2.78%	-2.90%
1 Month Performance	-24.00%	-5.85%	-6.28%	-5.10%
1 Year Performance	-97.73%	-4.89%	4.36%	-2.44%

IM Cannabis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMCC IM Cannabis	0.1771 of 5 stars	$1.33 -8.9%	N/A	-97.5%	$279K	$39.17M	N/A	44	Analyst Downgrade Short Interest Increase
ITRM Iterum Therapeutics	N/A	$0.03 flat	N/A	N/A	$1.60M	$390K	N/A	10
NKGN NKGen Biotech	N/A	$0.01 flat	N/A	+455.0%	$1.57M	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	0.3474 of 5 stars	$3.01 flat	N/A	-100.0%	$1.45M	$1.14M	N/A	56
JAGX Jaguar Animal Health	0.5573 of 5 stars	$4.07 -9.5%	N/A	-99.6%	$1.40M	$11.51M	N/A	47	Analyst Upgrade Short Interest Decrease Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMCC) was last updated on 10/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IM Cannabis (IMCC) Competitors

IMCC vs. ITRM, NKGN, SXTC, JAGX, and ATXI

How does IM Cannabis compare to Iterum Therapeutics?

Summary

How does IM Cannabis compare to NKGen Biotech?

Summary

How does IM Cannabis compare to China SXT Pharmaceuticals?

Summary

How does IM Cannabis compare to Jaguar Animal Health?

Summary

How does IM Cannabis compare to Avenue Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMCC vs. The Competition

IM Cannabis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

IM Cannabis (IMCC) Competitors

IMCC vs. ITRM, NKGN, SXTC, JAGX, and ATXI

How does IM Cannabis compare to Iterum Therapeutics?

Do analysts prefer IMCC or ITRM?

Is IMCC or ITRM more profitable?

Which has more volatility & risk, IMCC or ITRM?

Do insiders and institutionals hold more shares of IMCC or ITRM?

Which has preferable earnings & valuation, IMCC or ITRM?

Does the media favor IMCC or ITRM?

Summary

How does IM Cannabis compare to NKGen Biotech?

Do analysts rate IMCC or NKGN?

Does the media favor IMCC or NKGN?

Which has more volatility & risk, IMCC or NKGN?

Do institutionals & insiders have more ownership in IMCC or NKGN?

Which has better earnings and valuation, IMCC or NKGN?

Is IMCC or NKGN more profitable?

Summary

How does IM Cannabis compare to China SXT Pharmaceuticals?

Do analysts rate SXTC or IMCC?

Is SXTC or IMCC more profitable?

Do insiders & institutionals hold more shares of SXTC or IMCC?

Does the media refer more to SXTC or IMCC?

Which has more risk and volatility, SXTC or IMCC?

Which has preferable earnings & valuation, SXTC or IMCC?

Summary

How does IM Cannabis compare to Jaguar Animal Health?

Does the media favor IMCC or JAGX?

Do analysts rate IMCC or JAGX?

Do institutionals and insiders hold more shares of IMCC or JAGX?

Which has more volatility and risk, IMCC or JAGX?

Is IMCC or JAGX more profitable?

Which has higher earnings and valuation, IMCC or JAGX?

Summary

How does IM Cannabis compare to Avenue Therapeutics?

Does the media prefer IMCC or ATXI?

Which has higher valuation & earnings, IMCC or ATXI?

Do institutionals & insiders hold more shares of IMCC or ATXI?

Do analysts recommend IMCC or ATXI?

Which has more volatility and risk, IMCC or ATXI?

Is IMCC or ATXI more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMCC vs. The Competition

IM Cannabis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools